Dabigatran anticoagulation and Stanford type A aortic dissection: Lethal coincidence: Case report with literature review

Acta Anaesthesiologica Scandinavica

Volumn 58, Issue 5, 2014, Pages 630-637

  Stein, P ^a   Bosshart, M ^a   Brand, B ^a   Schlicker, A ^a   Spahn, D R ^a   Bettex, D ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BICARBONATE; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 13; BLOOD CLOTTING FACTOR 5; CEFUROXIME; DABIGATRAN; FRESH FROZEN PLASMA; HEPARIN; LACTIC ACID; MANNITOL; NEBIVOLOL; NORADRENALIN; PERINDOPRIL; PROTAMINE; PROTHROMBIN COMPLEX; RECOMBINANT BLOOD CLOTTING FACTOR 7A; TRANEXAMIC ACID; VASOPRESSIN; VON WILLEBRAND FACTOR; ANTICOAGULANT AGENT; BENZIMIDAZOLE DERIVATIVE; DABIGATRAN ETEXILATE; PYRIDINE DERIVATIVE;

AGED; ANTIBIOTIC PROPHYLAXIS; ANTICOAGULANT THERAPY; AORTA ANEURYSM; AORTA CLAMPING; AORTA DISSECTION; AORTA PROSTHESIS; AORTA RECONSTRUCTION; AORTA ROOT; AORTA VALVE; AORTA VALVE REGURGITATION; AORTA WALL; ARTERIAL LINE; ARTERY CATHETERIZATION; ASCENDING AORTA; BLEEDING; BLOOD CLOTTING DISORDER; BLOOD FLOW; BLOOD VOLUME; BRAIN PERFUSION; CARDIOPLEGIA; CARDIOPULMONARY BYPASS; CARDIOVERSION; CASE REPORT; CENTRAL VENOUS CATHETER; CRYSTALLOID; ECHOCARDIOGRAPHY; EMERGENCY SURGERY; ENDOTRACHEAL INTUBATION; ERYTHROCYTE CONCENTRATE; ERYTHROCYTE TRANSFUSION; FEMALE; FIBRINOLYSIS; HEART ATRIUM APPENDAGE; HEART ATRIUM FIBRILLATION; HEART LEFT VENTRICLE HYPERTROPHY; HEART MASSAGE; HEART RIGHT VENTRICLE FUNCTION; HEART TAMPONADE; HEMATOMA; HEMODIAFILTRATION; HEMODYNAMICS; HEMOSTASIS; HUMAN; HYPERTENSION; INFERIOR CAVA VEIN; INTENSIVE CARE UNIT; INTERNATIONAL NORMALIZED RATIO; JUGULAR VEIN; LONG TERM CARE; METABOLIC ACIDOSIS; OPERATIVE BLOOD LOSS; PERICARDIAL EFFUSION; PLASMA TRANSFUSION; PRIORITY JOURNAL; RADIAL ARTERY; REVIEW; STERNOTOMY; SUBCLAVIAN ARTERY; THORAX DRAINAGE; THORAX PAIN; THROMBIN TIME; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; THROMBOELASTOGRAPHY; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; ANEURYSM, DISSECTING; AORTIC ANEURYSM, THORACIC; ATRIAL FIBRILLATION; BLOOD; BLOOD CLOTTING TEST; BLOOD COMPONENT THERAPY; CARDIAC TAMPONADE; CHEMICALLY INDUCED; COMPLICATION; EMERGENCY; FATALITY; HEART VALVE REPLACEMENT; MALE; SHOCK, HEMORRHAGIC;

AGED; ANEURYSM, DISSECTING; ANTICOAGULANTS; AORTIC ANEURYSM, THORACIC; AORTIC VALVE INSUFFICIENCY; ATRIAL FIBRILLATION; BENZIMIDAZOLES; BLOOD COAGULATION FACTORS; BLOOD COAGULATION TESTS; BLOOD COMPONENT TRANSFUSION; CARDIAC TAMPONADE; CARDIOPULMONARY BYPASS; EMERGENCIES; FATAL OUTCOME; HEART VALVE PROSTHESIS IMPLANTATION; HEMODIAFILTRATION; HEPARIN; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; MALE; PYRIDINES; SHOCK, HEMORRHAGIC; THROMBELASTOGRAPHY; TRANEXAMIC ACID;

EID: 84898779802     PISSN: 00015172     EISSN: 13996576     Source Type: Journal    
DOI: 10.1111/aas.12303     Document Type: Review

References (33)

1. Hiratzka LF, Bakris GL, Beckman JA, Bersin RM, Carr VF, Casey DE, Eagle KA, Hermann LK, Isselbacher EM, Kazerooni EA, Kouchoukos NT, Lytle BW, Milewicz DM, Reich DL, Sen S, Shinn JA, Svensson LG, Williams DM, American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, American Association for Thoracic Surgery, American College of Radiology, American Stroke Association, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of Thoracic Surgeons, Society for Vascular Medicine. 2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM guidelines for the diagnosis and management of patients with thoracic aortic disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, American Association for Thoracic Surgery, American College of Radiology, American Stroke Association, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of Thoracic Surgeons, and Society for Vascular Medicine. Circulation 2010; 121: e266-369.
2. Golledge J, Eagle KA,. Acute aortic dissection. Lancet 2008; 372: 55-66.
3. Hagan PG, Nienaber CA, Isselbacher EM, Bruckman D, Karavite DJ, Russman PL, Evangelista A, Fattori R, Suzuki T, Oh JK, Moore AG, Malouf JF, Pape LA, Gaca C, Sechtem U, Lenferink S, Deutsch HJ, Diedrichs H, Marcos y Robles J, Llovet A, Gilon D, Das SK, Armstrong WF, Deeb GM, Eagle KA,. The International Registry of Acute Aortic Dissection (IRAD): new insights into an old disease. JAMA 2000; 283: 897-903.
4. Stangier J, Rathgen K, Stähle H, Gansser D, Roth W,. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol 2007; 64: 292-303.
5. Blech S, Ebner T, Ludwig-Schwellinger E, Stangier J, Roth W,. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos 2008; 36: 386-399.
6. Douxfils J, Mullier F, Robert S, Chatelain C, Chatelain B, Dogné J-M,. Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate. Thromb Haemost 2012; 107: 985-997.
7. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener H-C, Joyner CD, Wallentin L, RE-LY Steering Committee and Investigators. Dabigatran vs. warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-1151.
8. Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H, Baanstra D, Schnee J, Goldhaber SZ, RE-COVER Study Group. Dabigatran vs. warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009; 361: 2342-2352.
9. Eikelboom JW, Connolly SJ, Brueckmann M, Granger CB, Kappetein AP, Mack MJ, Blatchford J, Devenny K, Friedman J, Guiver K, Harper R, Khder Y, Lobmeyer MT, Maas H, Voigt J-U, Simoons ML, Van de Werf F, Investigators RE-ALIGN. Dabigatran vs. warfarin in patients with mechanical heart valves. N Engl J Med 2013; 369: 1206-1214.
10. Cotton BA, McCarthy JJ, Holcomb JB,. Acutely injured patients on dabigatran. N Engl J Med 2011; 365: 2039-2040.
11. Huang GS, Chance EA,. When dabigatran and trauma collide. Am Surg 2013; 79: 113-114.
12. Warkentin TE, Margetts P, Connolly SJ, Lamy A, Ricci C, Eikelboom JW,. Recombinant factor VIIa (rFVIIa) and hemodialysis to manage massive dabigatran-associated postcardiac surgery bleeding. Blood 2012; 119: 2172-2174.
13. Garber ST, Sivakumar W, Schmidt RH,. Neurosurgical complications of direct thrombin inhibitors-catastrophic hemorrhage after mild traumatic brain injury in a patient receiving dabigatran. J Neurosurg 2012; 116: 1093-1096.
14. Chang DN, Dager WE, Chin AI,. Removal of dabigatran by hemodialysis. Am J Kidney Dis 2013; 61: 487-489.
15. Truumees E, Gaudu T, Dieterichs C, Geck M, Stokes J,. Epidural hematoma and intraoperative hemorrhage in a spine trauma patient on Pradaxa (dabigatran). Spine 2012; 37: E863-865.
16. Mastrobuoni S, Robblee JA, Boodhwani M,. Spontaneous ascending aortic intramural haematoma in a patient on dabigatran. Interact Cardiovasc Thorac Surg 2012; 15: 299-300.
17. Croft PE, Cabral KP, Strout TD, Baumann MR, Gibbs MA, Delaney MC,. Managing blunt trauma in patients receiving dabigatran etexilate: case study and review of the literature. J Emerg Nurs 2013; 39: 302-308.
18. Dager WE, Gosselin RC, Roberts AJ,. Reversing dabigatran in life-threatening bleeding occurring during cardiac ablation with factor eight inhibitor bypassing activity. Crit Care Med 2013; 41: e42-46.
19. Harinstein LM, Morgan JW, Russo N,. Treatment of dabigatran-associated bleeding: case report and review of the literature. J Pharm Pract 2013; 26: 264-269.
20. Chen BC, Sheth NR, Dadzie KA, Smith SW, Nelson LS, Hoffman RS, Winchester JF,. Hemodialysis for the treatment of pulmonary hemorrhage from dabigatran overdose. Am J Kidney Dis 2013; 62: 591-594.
21. Singh T, Maw TT, Henry BL, Pastor-Soler NM, Unruh ML, Hallows KR, Nolin TD,. Extracorporeal therapy for dabigatran removal in the treatment of acute bleeding: a single center experience. Clin J Am Soc Nephrol 2013; 8: 1533-1539.
22. Healey JS, Eikelboom J, Douketis J, Wallentin L, Oldgren J, Yang S, Themeles E, Heidbuchel H, Heidbuchle H, Avezum A, Reilly P, Connolly SJ, Yusuf S, Ezekowitz M, RE-LY Investigators. Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial. Circulation 2012; 126: 343-348.
23. Stangier J, Rathgen K, Stähle H, Mazur D,. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Clin Pharmacokinet 2010; 49: 259-268.
24. Liesenfeld K-H, Staab A, Härtter S, Formella S, Clemens A, Lehr T,. Pharmacometric characterization of dabigatran hemodialysis. Clin Pharmacokinet 2013; 52: 453-462.
25. van Ryn J, Stangier J, Haertter S, Liesenfeld K-H, Wienen W, Feuring M, Clemens A,. Dabigatran etexilate-a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010; 103: 1116-1127.
26. Zhou W, Schwarting S, Illanes S, Liesz A, Middelhoff M, Zorn M, Bendszus M, Heiland S, van Ryn J, Veltkamp R,. Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran. Stroke 2011; 42: 3594-3599.
27. Pragst I, Zeitler SH, Doerr B, Kaspereit FJ, Herzog E, Dickneite G, van Ryn J,. Reversal of dabigatran anticoagulation by prothrombin complex concentrate (Beriplex P/N) in a rabbit model. J Thromb Haemost 2012; 10: 1841-1848.
28. Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M,. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 2011; 124: 1573-1579.
29. Davis PK, Musunuru H, Walsh M, Mitra R, Ploplis V, Castellino FJ,. The ex vivo reversibility of dabigatran-induced whole-blood coagulopathy as monitored by thromboelastography: mechanistic implications for clinical medicine. Thromb Haemost 2012; 108: 586-588.
30. Levi M, Levy JH, Andersen HF, Truloff D,. Safety of recombinant activated factor VII in randomized clinical trials. N Engl J Med 2010; 363: 1791-1800.
31. Marlu R, Hodaj E, Paris A, Albaladejo P, Cracowski JL, Crackowski JL, Pernod G,. Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers. Thromb Haemost 2012; 108: 217-224.
32. Schiele F, van Ryn J, Canada K, Newsome C, Sepulveda E, Park J, Nar H, Litzenburger T,. A specific antidote for dabigatran: functional and structural characterization. Blood 2013; 121: 3554-3562.
33. Esnault P, Gaillard PE, Cotte J, Cungi PJ, Beaume J, Prunet B,. Haemodialysis before emergency surgery in a patient treated with dabigatran. Br J Anaesth 2013; 111: 776-777.